Search

Search Constraints

You searched for: Author/Creator Alhan, Canan

Search Results

1. Absence of aberrant myeloid progenitors by flow cytometry is associated with favorable response to azacitidine in higher risk myelodysplastic syndromes. Issue 3 (28th January 2014)

3. Clinical application of flow cytometry in patients with unexplained cytopenia and suspected myelodysplastic syndrome: A report of the European LeukemiaNet International MDS‐Flow Cytometry Working Group. Issue 1 (13th December 2021)

4. Distinct bone marrow immunophenotypic features define the splicing factor 3B subunit 1 (SF3B1)‐mutant myelodysplastic syndromes subtype. (25th March 2021)

5. Dysplasia and PNH‐type cells in bone marrow aspirates of myelodysplastic syndromes. Issue 2 (22nd November 2021)

6. Flow cytometric analysis of myelodysplasia: Pre‐analytical and technical issues—Recommendations from the European LeukemiaNet. Issue 1 (11th December 2021)

7. Genomic array as compared to karyotyping in myelodysplastic syndromes in a prospective clinical trial. Issue 7 (31st March 2017)

8. High flow cytometric scores identify adverse prognostic subgroups within the revised international prognostic scoring system for myelodysplastic syndromes. (30th June 2014)

10. Multiparameter flow cytometry in the evaluation of myelodysplasia: Analytical issues: Recommendations from the European LeukemiaNet/International Myelodysplastic Syndrome Flow Cytometry Working Group. Issue 1 (20th December 2022)